Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy

Acta Myologica

Volumn 24, Issue 3, 2005, Pages 230-241

  Patel, Ketan ^a   Macharia, R ^a   Amthor, H ^b  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Duchenne; Dystrophy; Hypertrophy; Insulin Growth Factor; Muscle; Myostatin

Indexed keywords

BINDING PROTEIN; MYOSTATIN; SOMATOMEDIN C;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; DUCHENNE MUSCULAR DYSTROPHY; MOLECULAR MECHANICS; MUSCLE GROWTH; MUSCLE HYPERTROPHY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED MDX; MUSCLE DEVELOPMENT; MUSCLE HYPERTONIA; MUSCULAR DYSTROPHY, DUCHENNE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33645345963     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Wagner KR. Genetic diseases of muscle. Neurol Clin 2002;20:645-78.
2. Athanasopoulos T, Graham IR, Foster H, et al Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 2004;11 Suppl 1:5109-21
3. Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002;157:137-48.
4. Carroll PV, Van den Berghe G. Safety aspects of pharmacological GH therapy in adults. Growth Horm IGF Res 2001;11:166-72.
5. Shimatsu A, Rotwein P. Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene. J Biol Chem 1987;262:7894-900.
6. Shavlakadze T, Winn N, Rosenthal N, et al. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 2005;15:4-18
7. Etherton TD. Somatotropic function: the somatomedin hypothesis revisited. J Anim Sci 2004;82:E239-2
8. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324-9.
9. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
10. O. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200.
11. Allen RE, Boxhorn LK. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol 1989;138:311-5.
12. Stedman HH, Sweeney HL, Shrager JB, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991;352:536-9.
13. Delaughter MC, Taffet GE, Fiorotto ML, et al. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J 1999;13:1923-9.
14. Steele-Perkins G, Turner J, Edman JC, et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988;263:11486-92.
15. Myers MG Jr, Sun XJ, Cheatham B, et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3′-kinase. Endocrinology 1993;132:1421-30.
16. Myers MG Jr, White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993;42:643-50.
17. Coolican SA, Samuel DS, Ewton DZ, et al. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997;272:6653-62
18. Brogiolo W, Stocker H, Ikeya T, et al. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol 2001;11:213-21.
19. Xu Q, Wu Z. The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem 2000;275:36750-7.
20. Zhang H, Stallock JP, Ng JC, et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 2000;14:2712-24.
21. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
22. Montagne J, Stewart MJ, Stocker H, et al. Drosophila S6 kinase: a regulator of cell size. Science 1999;285:2126-9.
23. Hara K, Yonezawa K, Kozlowski MT, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997;272:26457-63.
24. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9.
25. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
26. Tintignac LA, Lagirand J, Batonnet S, et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 2005;280:2847-56.
27. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
28. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
29. Solomon V, Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996;271:26690-7.
30. Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 2000;6:849-51.
31. Musaro A, Giacinti C, Borsellino G, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A. 2004;101:1206-10
32. Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999;401:390-4.
33. McPherron A C, Lawler A M and Lee S J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
34. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A 1998;95:14938-43.
35. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999;180:1-9.
36. McFarlane C, Langley B, Thomas M, et al. Proteolytic processing of myostatin is auto-regulated during myogenesis. Dev Biol 2005;283:58-69.
37. Miyazono K, Hellman U, Wernstedt C, et al. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988;263:6407-15.
38. Wolfman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A 2003;100:15842-6.
39. Lee SJ and McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001;98:9306-11.
40. Grobet L, Pirottin D, Farnir F, et al. Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 2003;35:227-38.
41. Culley G. Observations on Livestock. 1807:London: Woodfall, G.
42. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8.
43. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8.
44. Wagner KR, McPherron AC, Winik N, et al. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002;52:832-6.
45. He L, Vichev K, Macharia R, et al. Activin A inhibits formation of skeletal muscle during chick development. Anat Embryol (Berl) 2005;209:401-7
46. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-21.
47. Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000;275:40235-43.
48. Langley B, Thomas M, Bishop A, et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem. 2002;277:49831-40.
49. Menke A. & Jockusch H. Extent of shock-induced membrane leakage in human and mouse myotubes depends on dystrophin. J Cell Sci 1995;108 (Pt 2):727-33.
50. Merlini L, Kaplan JC, Navarro C, et al. Homogeneous phenotype of the gypsy limb-girdle MD with the gamma-sarcoglycan C283Y mutation. Neurology 2000;54:1075-9.
51. Reimers CD, Schlotter B, Eicke BM, et al. Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature. J Neurol Sci 1996;143:46-56.
52. Lynch GS, Hinkle RT, Chamberlain JS, et al. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001;535:591-600.
53. Sasaoka T, Imamura M, Araishi K, et al. Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in gamma-sarcoglycan- deficient mice. Neuromuscul Disord 2003;13:193-206.
54. Araishi K, Sasaoka T, Imamura M, et al. Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice. Hum Mol Genet 1999;8:1589-98.
55. Carpenter JL, Hoffman EP, Romanul FC, et al. Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 1989;135:909-19.
56. Gaschen FP, Hoffman EP, Gorospe JR, et al. Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 1992;110:149-59
57. Charge SB, Brack AS & Hughes SM Aging-related satellite cell differentiation defect occurs prematurely after Ski-induced muscle hypertrophy. Am J Physiol Cell Physiol 2002;283:C1228-41.
58. Holmes JH, Ashmore CR & Robinson DW. Effects of stress on cattle with hereditary muscular hypertrophy. J Anim Sci 1973;36:684-94.
59. Liu W, Thomas SG, Asa SL, et al. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab 2003;88:5490-6.
60. Reardon KA, Davis J, Kapsa RM, et al. Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy. Muscle Nerve 2001;24:893-9.